Skip to main content
Fig. 8 | Journal of Experimental & Clinical Cancer Research

Fig. 8

From: Combined inhibition of HER2 and VEGFR synergistically improves therapeutic efficacy via PI3K-AKT pathway in advanced ovarian cancer

Fig. 8

RC48 and CM synergistically inhibit tumor growth in OC PDX models. A OC-52 and OC-94 PDX-derived cells were isolated in vitro, and treated with VEH, 10 μg/mL RC48, 2 µM CM or their COM for 5 days. Cell viability was assessed using Cell Titer-Glo cytotoxicity assays. B In both PDX models, mice were intravenously administered with VEH, 2.0 MPK RC48 (once a week for 3 times), 0.5 MPK CM (once every day), and their COM. Tumor growth curves were evaluated in OC-52 and OC-94 PDX models. C, D Representative IHC image of Ki‐67 staining (proliferation index) in OC-52 (upper panel) and OC-94 (lower panel) xenograft tumors. Images were captured with TissueFAXS Plus at 400 × magnification. Scale bars = 20 µm. E, F The quantification of apoptotic cells in OC-52 (upper panel) and OC-94 (lower panel) xenograft tumors was determined by TUNEL assay. Apoptotic cells are represented by green fluorescent-stained cell nuclei. Images were captured using LSCM at 400 × magnification. Scale bars = 20 µm. The data shown represent the mean ± SEM from three independent experiments performed in triplicate. All treated groups compared to VEH group or COM group compared to single agent group. Statistically significant values are denoted as *p < 0.05, **p < 0.01, and ***p < 0.001

Back to article page